Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
In patients with MASH and moderate or advanced liver fibrosis, once-weekly semaglutide at a dose of 2.4 mg improved liver histologic results. (Funded by Novo Nordisk; ClinicalTrials.gov number, NCT04822181.).
Authors
- Vlad Ratziu (ORCID: https://orcid.org/0000-0002-3051-0111)
- Michael Roden (ORCID: https://orcid.org/0000-0001-8200-6382)
- Elisabetta Bugianesi (ORCID: https://orcid.org/0000-0002-0502-4381)
- Philip N. Newsome (ORCID: https://orcid.org/0000-0001-6085-3652)
- Michelle T. Long (ORCID: https://orcid.org/0000-0001-6131-3981)
- Iris Kliers
- Mette Skalshøi Kjær (ORCID: https://orcid.org/0000-0001-6322-4077)
- Laura Østergaard
- Mary E. Rinella
- Anna M.G. Cali
Institutions
- Inserm (FR)
- King's College London (GB)
- Virginia Commonwealth University (US)
- Novo Nordisk (Denmark) (DK)
- Foundation for Liver Research (GB)
- Sorbonne Université (FR)
- University of Chicago (US)
- Düsseldorf University Hospital (DE)
- Centre de Recherche des Cordeliers (FR)
- Deutsches Diabetes-Zentrum e.V. (DE)
- King's College Hospital (GB)
- Fondation pour l’innovation en Cadiométabolisme et Nutrition (FR)
- German Center for Diabetes Research (DE)
- Heinrich Heine University Düsseldorf (DE)
- University of Turin (IT)
- University of Birmingham (GB)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-04-30
- DOI
- https://doi.org/10.1056/nejmoa2413258
- Citations
- 468
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 633.76
Funders
- Novo Nordisk